Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)Dose Escalation Study to Evaluate the Safety/Tolerability and Efficacy of EA-2353 in Subjects With Retinitis Pigmentosa
Phase 1
Terminated
- Conditions
- Retinitis Pigmentosa SyndromeRetinitis Pigmentosa
- Interventions
- First Posted Date
- 2022-05-26
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Endogena Therapeutics, Inc
- Target Recruit Count
- 14
- Registration Number
- NCT05392751
- Locations
- 🇺🇸
Endogena Site 005, Miami, Florida, United States
🇺🇸Endogena Site 003, Ann Arbor, Michigan, United States
🇺🇸Endogena Site 004, Portland, Oregon, United States
News
No news found